These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26199990)

  • 1. Volatile Organic Compounds in Exhaled Air as Novel Marker for Disease Activity in Crohn's Disease: A Metabolomic Approach.
    Bodelier AG; Smolinska A; Baranska A; Dallinga JW; Mujagic Z; Vanhees K; van den Heuvel T; Masclee AA; Jonkers D; Pierik MJ; van Schooten FJ
    Inflamm Bowel Dis; 2015 Aug; 21(8):1776-85. PubMed ID: 26199990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitis.
    Smolinska A; Bodelier AG; Dallinga JW; Masclee AA; Jonkers DM; van Schooten FJ; Pierik MJ
    Aliment Pharmacol Ther; 2017 May; 45(9):1244-1254. PubMed ID: 28239876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn's disease and ulcerative colitis.
    Dryahina K; Smith D; Bortlík M; Machková N; Lukáš M; Španěl P
    J Breath Res; 2017 Nov; 12(1):016002. PubMed ID: 28781264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomic analysis of breath volatile organic compounds reveals unique breathprints in children with inflammatory bowel disease: a pilot study.
    Patel N; Alkhouri N; Eng K; Cikach F; Mahajan L; Yan C; Grove D; Rome ES; Lopez R; Dweik RA
    Aliment Pharmacol Ther; 2014 Sep; 40(5):498-507. PubMed ID: 25041596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Exhaled Breath Volatile Organic Compounds in Inflammatory Bowel Disease: A Pilot Study.
    Hicks LC; Huang J; Kumar S; Powles ST; Orchard TR; Hanna GB; Williams HR
    J Crohns Colitis; 2015 Sep; 9(9):731-7. PubMed ID: 26071410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive exhaled volatile organic biomarker analysis to detect inflammatory bowel disease (IBD).
    Arasaradnam RP; McFarlane M; Daulton E; Skinner J; O'Connell N; Wurie S; Chambers S; Nwokolo C; Bardhan K; Savage R; Covington J
    Dig Liver Dis; 2016 Feb; 48(2):148-53. PubMed ID: 26682719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory bowel disease and patterns of volatile organic compounds in the exhaled breath of children: A case-control study using Ion Molecule Reaction-Mass Spectrometry.
    Monasta L; Pierobon C; Princivalle A; Martelossi S; Marcuzzi A; Pasini F; Perbellini L
    PLoS One; 2017; 12(8):e0184118. PubMed ID: 28859138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Vavricka SR; Bruegger LE; Seibold F
    Am J Gastroenterol; 2010 Jan; 105(1):162-9. PubMed ID: 19755969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosing Inflammatory bowel disease using noninvasive applications of volatile organic compounds: a systematic review.
    Bannaga AS; Farrugia A; Arasaradnam RP
    Expert Rev Gastroenterol Hepatol; 2019 Nov; 13(11):1113-1122. PubMed ID: 31657950
    [No Abstract]   [Full Text] [Related]  

  • 11. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
    Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
    Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
    Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The faecal scent of inflammatory bowel disease: Detection and monitoring based on volatile organic compound analysis.
    Bosch S; Wintjens DSJ; Wicaksono A; Kuijvenhoven J; van der Hulst R; Stokkers P; Daulton E; Pierik MJ; Covington JA; de Meij TGJ; de Boer NKH
    Dig Liver Dis; 2020 Jul; 52(7):745-752. PubMed ID: 32402741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Volatile organic compounds in exhaled breath are independent of systemic inflammatory syndrome caused by intravenous lipopolysaccharide infusion in humans: results from an experiment in healthy volunteers.
    Peters AL; Gerritsen MG; Brinkman P; Zwinderman KAH; Vlaar APJ; Bos LD
    J Breath Res; 2017 Apr; 11(2):026003. PubMed ID: 28397711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease.
    Sipponen T; Savilahti E; Kärkkäinen P; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
    Inflamm Bowel Dis; 2008 Oct; 14(10):1392-8. PubMed ID: 18484671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach.
    Baranska A; Mujagic Z; Smolinska A; Dallinga JW; Jonkers DM; Tigchelaar EF; Dekens J; Zhernakova A; Ludwig T; Masclee AA; Wijmenga C; van Schooten FJ
    Aliment Pharmacol Ther; 2016 Jul; 44(1):45-56. PubMed ID: 27136066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects.
    Besa V; Teschler H; Kurth I; Khan AM; Zarogoulidis P; Baumbach JI; Sommerwerck U; Freitag L; Darwiche K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():399-406. PubMed ID: 25759572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics of volatile organic compounds in cystic fibrosis patients and controls.
    Robroeks CM; van Berkel JJ; Dallinga JW; Jöbsis Q; Zimmermann LJ; Hendriks HJ; Wouters MF; van der Grinten CP; van de Kant KD; van Schooten FJ; Dompeling E
    Pediatr Res; 2010 Jul; 68(1):75-80. PubMed ID: 20351658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Volatile metabolites in breath strongly correlate with gut microbiome in CD patients.
    Smolinska A; Tedjo DI; Blanchet L; Bodelier A; Pierik MJ; Masclee AAM; Dallinga J; Savelkoul PHM; Jonkers DMAE; Penders J; van Schooten FJ
    Anal Chim Acta; 2018 Sep; 1025():1-11. PubMed ID: 29801597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.